CytRx to Present at Upcoming Investor Conferences in New York City and Las Vegas
September 02 2014 - 6:00AM
Business Wire
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research
and development company specializing in oncology, today announced
that President and CEO Steven A. Kriegsman and Vice President of
Business Development and Investor Relations David Haen will present
at the following upcoming investor conferences:
- 16th Annual Rodman & Renshaw
Healthcare Conference on Tuesday, September 9, 2014 at 12:05 p.m.
Eastern Time at The New York Palace Hotel in New York City
- Aegis 2014 Healthcare & Technology
Conference on Friday, September 12, 2014 at 2:00 p.m. Pacific Time
at The Encore at Wynn in Las Vegas
Live and archived webcasts of the presentations will be
available on the company’s website at
www.cytrx.com/presentations.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and
development company specializing in oncology. CytRx currently is
focused on the clinical development of aldoxorubicin (formerly
known as INNO-206), its improved version of the widely used
chemotherapeutic agent doxorubicin. CytRx has initiated under a
special protocol assessment a pivotal Phase 3 global trial with
aldoxorubicin as a therapy for patients with soft tissue sarcomas
whose tumors have progressed following treatment with chemotherapy,
and recently announced that it has received approval from the FDA
to continue dosing patients with aldoxorubicin until disease
progression in that clinical trial. CytRx has initiated a Phase 2
clinical trial in HIV-related Kaposi’s sarcoma, and a Phase 2
clinical trial with aldoxorubicin in patients with late-stage
glioblastoma (brain cancer). CytRx has completed a global Phase 2b
clinical trial with aldoxorubicin as a first-line therapy for soft
tissue sarcomas, a Phase 1b/2 clinical trial primarily in the same
indication, a Phase 1b clinical trial of aldoxorubicin in
combination with doxorubicin in patients with advanced solid tumors
and a Phase 1b pharmacokinetics clinical trial in patients with
metastatic solid tumors. CytRx plans to expand its pipeline of
oncology candidates at its laboratory facilities in Freiburg,
Germany, based on novel linker technologies that can be utilized
with multiple chemotherapeutic agents and may allow for greater
concentration of drug at tumor sites. For more information about
CytRx Corporation, visit www.cytrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended. Such statements involve risks and uncertainties that
could cause actual events or results to differ materially from the
events or results described in the forward-looking statements,
including risks relating to the outcome, timing and results of
CytRx's clinical trials, the risk that any future human testing of
aldoxorubicin might not produce results similar to those seen in
past human or animal testing, risks related to CytRx's ability to
manufacture its drug candidates in a timely fashion,
cost-effectively or in commercial quantities in compliance with
stringent regulatory requirements, risks related to CytRx's need
for additional capital or strategic partnerships to fund its
ongoing working capital needs and development efforts, including
the Phase 3 clinical development of aldoxorubicin, risks related to
lawsuits that have been brought against the Company and its
officers and/or directors for alleged violations of the securities
laws, and the risks and uncertainties described in the most recent
annual and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report. All forward-looking statements
are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations:Argot PartnersMichelle Carroll,
212-600-1902michelle@argotpartners.comorMedia:Argot
PartnersEliza Schleifstein,
973-361-1546eliza@argotpartners.comorCompany:CytRx
CorporationDavid J. Haen, 310-826-5648, ext. 304Vice President,
Business Development and Investor Relationsdhaen@cytrx.com
Cytrx (NASDAQ:CYTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytrx (NASDAQ:CYTR)
Historical Stock Chart
From Apr 2023 to Apr 2024